ArQule, Inc.’s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib …
(Orginal – Story lesen…)
Business News
ArQule, Inc.’s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib …
(Orginal – Story lesen…)